Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel guanosine derivatives against MERS CoV polymerase: An in silico perspective

20 Apr 2020

Abstract excerpt

The Middle East Respiratory Syndrome Coronavirus (MERS CoV), also termed camel flu, is a new viral infection that first reported in the year 2012 in the Middle East region and further spread during the last seven years. MERS CoV is characterized by its high mortality rate among different human coronaviruses. MERS CoV polymerase shares more than 20% sequence identity with the Hepatitis C Virus (HCV) Non-structural...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Drug Discovery Methods
Share to SARS-CoV-2 and COVID-19 Research
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32306854
DOI: 10.1080/07391102.2020.1758789

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel guanosine derivatives against MERS CoV polymerase: An in silico perspectivePMID 32306854Read ↗

SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspectiveSemantic proximity Read ↗

Novel guanosine derivatives against Zika virus polymerase in silicoSemantic proximity Read ↗

Nucleotide and nucleoside-based drugs: past, present, and futureSemantic proximity Read ↗

Recent advances in the discovery of potent RNA-dependent RNA-polymerase (RdRp) inhibitors targeting virusesSemantic proximity Read ↗

Comparative molecular docking and simulation analysis of molnupiravir and remdesivir with SARS-CoV-2 RNA dependent RNA polymerase (RdRp)Semantic proximity Read ↗

A computational comparative analysis of the binding mechanism of molnupiravir's active metabolite to RNA‐dependent RNA polymerase of wild‐type and Delta subvariant AY.4 of SARS‐CoV‐2Semantic proximity Read ↗

A computational approach to drug repurposing against SARS-CoV-2 RNA dependent RNA polymerase (RdRp)Semantic proximity Read ↗

Computational Study of SARS-CoV-2 RNA Dependent RNA Polymerase Allosteric Site InhibitionSemantic proximity Read ↗

Remdesivir overcomes the S861 roadblock in SARS-CoV-2 polymerase elongation complexSemantic proximity Read ↗

Repurposing Remdesivir for COVID-19: Computational Drug Design Targeting SARS-CoV-2 RNA Polymerase and Main Protease using Molecular Dynamics ApproachSemantic proximity Read ↗

Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In SilicoSemantic proximity Read ↗

Impact of Remdesivir Incorporation along the Primer Strand on SARS-CoV-2 RNA-Dependent RNA PolymeraseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.